{
    "Trade/Device Name(s)": [
        "ADVIA Centaur CA 15-3 assay",
        "ADVIA Centaur CA 15-3"
    ],
    "Submitter Information": "Siemens Healthcare Diagnostics Inc.",
    "510(k) Number": "K192777",
    "Predicate Device Reference 510(k) Number(s)": [
        "K012357"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "MOI"
    ],
    "Summary Letter Date": "November 22, 2019",
    "Summary Letter Received Date": "September 30, 2019",
    "Submission Date": "November 21, 2019",
    "Regulation Number(s)": [
        "21 CFR 866.6010"
    ],
    "Regulation Name(s)": [
        "Tumor-Associated Antigen Immunological Test System"
    ],
    "Analyte Class(es)": [
        "immunology",
        "cancer molecular"
    ],
    "Analyte(s)": [
        "Cancer antigen CA 15-3"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma (EDTA)",
        "Plasma (Lithium heparin)"
    ],
    "Specimen Container(s)": [
        "EDTA tube",
        "Lithium heparin tube"
    ],
    "Instrument(s)/Platform(s)": [
        "ADVIA Centaur",
        "ADVIA Centaur XP",
        "ADVIA Centaur XPT"
    ],
    "Method(s)/Technology(ies)": [
        "Sandwich immunoassay",
        "Direct chemiluminescent"
    ],
    "Methodologies": [
        "Immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent",
        "Calibrator",
        "Control"
    ],
    "Document Summary": "FDA 510(k) summary for ADVIA Centaur CA 15-3 assay, an in vitro immunoassay for quantitative measurement of cancer antigen CA 15-3 using ADVIA Centaur systems",
    "Indications for Use Summary": "Quantitative serial determination of cancer antigen CA 15-3 in human serum and plasma to monitor disease and therapy in metastatic breast cancer patients and detect recurrence in treated Stage II/III breast cancer, used with ADVIA Centaur systems",
    "fda_folder": "Immunology"
}